New sustainability magazine - Novo Nordisk's TBL Quarterly

Today, many parts of the Middle East and North Africa struggle with conflict and civil unrest. What is perhaps less known is the threat diabetes poses, responsible for 367,700 premature deaths each year.[1] The new issue of Novo Nordisk’s TBL Quarterly tells the stories about the actions that are taken to create better health in the region.

 Today, Novo Nordisk published the 6^th issue of its quarterly sustainability magazine, TBL Quarterly. The new issue, Beyond conflict - putting the focus on health in the Middle East, shows how the company is working to improve health in countries that have some of the world’s highest comparative prevalence of diabetes. Through articles, personal stories and interviews, the TBL Quarterly among other things shows how Novo Nordisk is securing insulin supply in Israel and the Palestinian territories, raising awareness about diabetes in Algeria, and building healthcare professionals’ capabilities in Egypt.

Download the issue ‘Beyond conflict – putting the focus on health in the Middle East’ here.

According the latest figures from the International Diabetes Federation, 1 out of 10 adults in the Middle East and North Africa has diabetes and in the wealthy Gulf States like Saudi Arabia, Kuwait and Qatar the prevalence rate is as high as 1 out of 5. In total, almost 35 million people are living with diabetes today and the number is set to almost double by 2035.[2]

Despite political uncertainty and civil conflict in some of the region’s countries, the stories in TBL Quarterly tell how Novo Nordisk has maintained its commitment and efforts to provide diabetes treatments and care.

The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to sustainability@novonordisk.com.

About the TBL Quarterly

Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both the company and its stakeholders.  Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.

Explore previous issues of the TBL Quarterly

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

Read more about Novo Nordisk’s Triple Bottom Line approach to business

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk